Earnings summaries and quarterly performance for CHARLES RIVER LABORATORIES INTERNATIONAL.
Executive leadership at CHARLES RIVER LABORATORIES INTERNATIONAL.
James C. Foster
Detailed
Chair, President and Chief Executive Officer
CEO
BG
Birgit Girshick
Detailed
Corporate Executive Vice President and Chief Operating Officer
JW
Joseph W. LaPlume
Detailed
Corporate Executive Vice President, Corporate Development & Strategy
MG
Michael G. Knell
Detailed
Interim Chief Financial Officer
VC
Victoria Creamer
Detailed
Corporate Executive Vice President and Chief People Officer
Board of directors at CHARLES RIVER LABORATORIES INTERNATIONAL.
AC
Abraham Ceesay
Detailed
Director
CB
Craig B. Thompson
Detailed
Director
GL
George Llado, Sr.
Detailed
Director
ME
Mark Enyedy
Detailed
Director
MW
Martin W. Mackay
Detailed
Lead Independent Director
NC
Nancy C. Andrews
Detailed
Director
PG
Paul Graves
Detailed
Director
RK
Reshema Kemps-Polanco
Detailed
Director
SB
Steven Barg
Detailed
Director
VM
Virginia M. Wilson
Detailed
Director
Research analysts who have asked questions during CHARLES RIVER LABORATORIES INTERNATIONAL earnings calls.
CW
Casey Woodring
JPMorgan Chase & Co.
6 questions for CRL
Also covers: A, AVTR, BLLN +15 more
Michael Ryskin
Bank of America Merrill Lynch
6 questions for CRL
Also covers: A, ALGN, AVTR +29 more
Patrick Donnelly
Citi
6 questions for CRL
Also covers: A, AVTR, BIO +24 more
CR
Charles Rhyee
TD Cowen
5 questions for CRL
Also covers: AMWL, BTSG, CAH +20 more
Elizabeth Anderson
Evercore ISI
5 questions for CRL
Also covers: AGL, ALGN, CAH +24 more
EC
Eric Coldwell
Robert W. Baird & Co.
5 questions for CRL
Also covers: ACH, AHCO, CAH +11 more
JB
Justin Bowers
Deutsche Bank AG
5 questions for CRL
Also covers: AMED, CON, CTLT +9 more
DW
David Windley
Jefferies Financial Group Inc.
4 questions for CRL
Also covers: CERT, CNC, CTLT +15 more
MS
Max Smock
William Blair & Company
4 questions for CRL
Also covers: CDMO, CERT, CTLT +8 more
Luke Sergott
Barclays
3 questions for CRL
Also covers: A, AVTR, BRKR +20 more
TS
Tejas Savant
Morgan Stanley
3 questions for CRL
Also covers: ADPT, AKYA, AVTR +20 more
AH
Ann Hynes
Mizuho Financial Group
2 questions for CRL
Also covers: ACHC, ARDT, BTSG +21 more
Christine Rains
William Blair
2 questions for CRL
Also covers: CERT, ICLR, IQV +3 more
Dave Windley
Jefferies LLC
2 questions for CRL
Also covers: CERT, CNC, ELV +8 more
Joshua Waldman
Cleveland Research Company
2 questions for CRL
Also covers: A, BRKR, ICLR +1 more
MS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for CRL
Also covers: A, ADPT, AVTR +21 more
AK
Anna Kruszenski
Barclays
1 question for CRL
Also covers: CERT
DL
Daniel Leonard
Stifel Financial Corp.
1 question for CRL
Also covers: A, AVTR, BIO +15 more
Elizabeth Anderson
Evercore
1 question for CRL
Also covers: CAH, CVS
JJ
Jacob Johnson
Stephens Inc.
1 question for CRL
Also covers: AZTA, CDMO, CDXS +13 more
KC
Kyle Cruise
UBS
1 question for CRL
Also covers: WST
MS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for CRL
Also covers: CTKB, MRVI, NTRA +4 more
Recent press releases and 8-K filings for CRL.
Charles River Labs outlines demand recovery and portfolio repositioning
CRL
M&A
New Projects/Investments
- Charles River sees a biotech funding trough turning into a demand rebound, citing a 9-month backlog and its strongest quarter last Q4, with January–February also robust.
- The company is divesting its CDMO business and acquiring a biologics NAMS platform plus an NHP supply business to sharpen its core offerings and boost margins.
- Management emphasizes investment in non-animal models (NAMS) and AI as complementary discovery tools, expecting meaningful impact over the next decade.
- Charles River is evaluating a larger footprint in China to capture safety work on China-originated drugs and raise local standards, as the country becomes the world’s No. 2 in drug development.
1 day ago
Charles River Labs highlights turning biotech demand and strategic focus at Barclays Healthcare Conference
CRL
Revenue Acceleration/Inflection
M&A
- Charles River sees biotech‐funded demand bottoming with a very strong Q4, January–February momentum, over 1.1× book-to-bill in 4Q and a ~9-month backlog.
- Emphasizes incremental tech investments (automation, digital) and cautious AI/NAMS integration, expecting a ~10-year horizon for AI impact and pursuing selective NAMS acquisitions amid client data-sharing hurdles.
- Streamlining the portfolio by divesting underperforming CDMO operations and acquiring a biologics NAMS and a vertically integrated NHP supply business to secure capacity, improve margins and leverage core wet-lab expertise.
- Exploring an expanded foothold in China, where domestic pharma innovation is accelerating, with potential acquisitions to replicate Western safety‐testing standards as local workflows mature.
1 day ago
Charles River Laboratories outlines demand rebound and strategic M&A
CRL
M&A
Revenue Acceleration/Inflection
- Biotech funding rebound is driving a recovery in demand, with 4Q 2025 being the strongest in recent years and backlog at approximately nine months, signaling a positive inflection in R&D spending.
- To sharpen focus on core offerings, CRL is divesting its CDMO business and acquiring a biologics NAMS company and an NHP supply business (e.g., Noveprim), expected to enhance operating margins and ensure supply certainty.
- While AI and NAMS hold promise for accelerating discovery, full implementation—especially in safety—faces data‐sharing and validation hurdles, with meaningful impact likely over the next decade.
- CRL is evaluating expansion in China, where low‐cost discovery has given way to domestic innovation and outbound asset acquisitions, aiming to elevate safety services by partnering with or acquiring local players.
1 day ago
Charles River Labs outlines CEO transition and strategic plan at TD Cowen conference
CRL
CEO Change
M&A
Share Buyback
- Leadership Change: Birgit Girshick will succeed Jim Foster as CEO following an in-depth strategic review to sharpen the company’s focus on high-value services.
- M&A Activity: Completed two acquisitions—integration of non-human primate supply chain and next-generation sequencing methods—and signed definitive agreements to divest CDMO, Cell Solutions, and certain European discovery services.
- Operational Metrics & Outlook: Achieved a net book-to-bill >1 in Q4 2025, supporting confidence in returning to organic growth in H2 2026, alongside a digital transformation expected to deliver $300 million in cost savings.
- Margin Improvement: The K.F. Cambodia acquisition is projected to boost DSA segment margins by 50 bps and overall company margins by 100 bps, while normalizing non-human primate costs after Q1 2026.
- Capital Allocation: With a depressed share price, Charles River plans to resume share repurchases in 2026, while continuing to prioritize debt reduction and M&A investments.
Mar 3, 2026, 2:50 PM
Charles River outlines strategic review outcomes and 2026 outlook
CRL
Guidance Update
M&A
Share Buyback
- Leadership transition: Incoming CEO Birgit Girshick emphasized execution of a strategic review that led to two acquisitions (NHP supply chain integration and NGS-based services) and signed agreements to divest CDMO, Cell Solutions, and certain European discovery assets, while retaining ~60% of NAMS revenue.
- Demand trends: Achieved net book-to-bill >1 in Q4 2025, with biotech bookings recovering since summer and pharma accelerating clinical candidates; company aims to sustain average net book-to-bill >1 to drive H2 2026 growth.
- Capital allocation: Despite guiding for a slight increase in share count, Charles River plans share repurchases in 2026 alongside debt reduction and continued opportunistic M&A.
- Margin dynamics: DSA margins to rebound as spot NHP costs normalize post-Q1 and the KFI acquisition contributes ~50 bps to segment margin; RMS segment faces a ~200 bps growth headwind due to 2026 third-party animal shipment timing.
- Regional expansion: China research models account for ~15% of the RMS segment (~4% of total revenue) and are rebounding; DSA services entry under evaluation; academic/government RMS demand is stable but experiencing slower growth.
Mar 3, 2026, 2:50 PM
Charles River Labs outlines CEO transition, M&A, and growth strategy
CRL
CEO Change
M&A
Share Buyback
- CEO transition: Birgit Girshick succeeds Jim Foster; a strategic review drove acquisitions of non-human primate supply chain and NGS alternative methods, plus divestitures of CDMO, Cell Solutions, and European discovery assets; digital transformation has removed $300 million in costs.
- Demand and backlog: Biotech proposals and bookings have improved since summer, with pharma accelerating clinical pipelines; net book-to-bill >1 in Q4 2025 supports H2 2026 revenue growth.
- Supply chain secured: Acquisition of KFI Cambodia to internalize non-human primate supply is expected to boost DSA margins by 50 bps and company margins by 100 bps.
- Capital allocation: After a pause, CRL plans to resume share buybacks in 2026 given current stock valuation.
- AI integration: CRL views AI as an evolutionary efficiency tool—with ~150 AI-assisted drug programs in the clinic—and is piloting AI for NAMs, reporting, and operations to reduce animal use and speed workflows.
Mar 3, 2026, 2:50 PM
Charles River Labs divests CDMO, Cell Solutions and European Discovery Services assets
CRL
M&A
Guidance Update
- Signed definitive agreement to sell CDMO and Cell Solutions businesses to GI Partners; these segments generated $143 million revenue in 2025.
- Agreed to divest European Discovery Services assets to IQVIA for approximately $145 million cash plus up to $10 million contingent payments.
- Transactions expected to close in Q2 2026; updated 2026 guidance reflects -5.0% to -3.5% reported revenue growth and raises non-GAAP EPS to $10.80–$11.30 with $0.10 accretion from divestitures.
Feb 25, 2026, 12:34 PM
Charles River Laboratories plans divestitures, updates 2026 guidance
CRL
M&A
Guidance Update
- Charles River signed definitive agreements to divest its CDMO and Cell Solutions businesses to GI Partners; these units generated $143 million in 2025 revenue (Manufacturing Solutions: $117 M; RMS: $26 M). Expected close: Q2 2026.
- The Company will sell certain European Discovery Services assets to IQVIA for approximately $145 million in cash (plus up to $10 M contingent), representing $144 million of 2025 Discovery and Safety Assessment revenue. Expected close: Q2 2026.
- Updated 2026 guidance (assumes Q2 2026 closings): reported revenue growth (5.0)%–(3.5)%, organic growth (1.5)%–(0.5)%, and non-GAAP EPS $10.80–$11.30 (includes ~$0.10 accretion).
- Divestitures are projected to reduce 2026 revenue by over $200 million and trim organic growth by >50 bps, while adding >100 bps to non-GAAP operating margin and ~$0.10 to EPS.
Feb 25, 2026, 12:00 PM
Charles River Labs reports Q4 2025 results
CRL
Earnings
CEO Change
Guidance Update
- Q4 revenue was $994.2 million, an organic decline of 2.6%; full-year 2025 revenue was $4.02 billion, organic down 1.6%.
- Q4 non-GAAP EPS was $2.39, down 10.2% y/y; FY non-GAAP EPS was $10.28, essentially flat y/y.
- 2026 guidance calls for organic revenue down 1% to flat, non-GAAP EPS of $10.70–11.20 (4–9% growth) and a 20–50 bp operating-margin improvement.
- Birgit Girshick will succeed James Foster as CEO in May 2026; Mike Knell continues as interim CFO.
- Closed acquisition of K.F. Cambodia assets and pending PathoQuest deal; targeting divestitures equal to ~7% of 2025 revenue by mid-2026.
Feb 18, 2026, 1:30 PM
Charles River Laboratories reports Q4 2025 results and 2026 guidance
CRL
Earnings
Guidance Update
CEO Change
- Q4 2025 revenue was $994.2 million, down 2.6% on an organic basis; full-year revenue was $4.02 billion, down 1.6% organic. Q4 non-GAAP EPS was $2.39 (–10.2%), and full-year EPS was $10.28 (flat).
- DSA demand strengthened with Q4 net book-to-bill improving to 1.12× on net bookings of $665 million and backlog rising to $1.86 billion.
- 2026 guidance calls for organic revenue down 1% to flat, non-GAAP EPS of $10.70–$11.20 (+4%–9%), and a 20–50 bp operating margin expansion, including $0.25 per share benefit from the K.F. Cambodia acquisition.
- CEO James Foster will retire at the May 5 annual meeting, succeeded by Birgit Girshick; Mike Knell has been named interim CFO.
- Strategic actions include closing the K.F. Cambodia acquisition, pending the PathoQuest deal, and executing divestitures totaling ~7% of 2025 revenue by mid-2026 to sharpen portfolio focus.
Feb 18, 2026, 1:30 PM
Quarterly earnings call transcripts for CHARLES RIVER LABORATORIES INTERNATIONAL.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more